Bronchiolitis obliterans (BO) is a fibroproliferative disorder that leads to epithelial injury and fibrotic constriction of the bronchioles. It is associated with various conditions, such as allogeneic hematopoietic stem cell transplantation (allo-SCT), lung transplantation, viral infections, connective tissue disease and exposure to toxic fumes. 1 BO is a major cause of morbidity and mortality following allo-SCT, with an overall survival rate of only 13% at 5 years. 2, 3 As is often the case with a fibrotic disorder, BO responds poorly to corticosteroids or immunosuppressants once it develops. Therefore, new treatment options are urgently needed to inhibit the progression of BO.
Molecular-targeted therapy is currently used to treat various malignancies. Tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib and dasatinib are now common treatments for Philadelphia chromosome-positive CML and acute lymphoid leukemia. 4 Their targets include PDGF receptor (PDGFR), and the tyrosine kinases c-Abl, and c-Kit. 4 Several studies have shown that imatinib can ameliorate chronic GVHD (cGVHD). [5] [6] [7] However, there are few published reports of studies that have focused on the efficacy of TKIs used to treat BO associated with cGVHD. Here, we describe two patients who had undergone allogeneic hematopoietic stem cell transplantation (allo-SCT) and developed biopsy-proven BO that was successfully treated with TKIs.
Case 1 was a 58-year-old woman who presented with progressive dyspnea on exertion. Eighteen months previously, she had undergone allo-SCT for CML and had obtained molecular remission. However, 6 months after allo-SCT, she developed cGVHD involving her skin, liver, mouth and eyes. The cGVHD lesions improved in response to corticosteroid and cyclosporine treatment. The corticosteroid dose was tapered from 45 to 10 mg per day, to a final dose reduction of 78%. The patient developed gradually worsening exertional dyspnea 18 months after undergoing SCT. Her forced expiratory volume in 1 s (FEV 1 ) and diffusing capacity of carbon monoxide (DLco) declined from 142% predicted and 80% predicted, respectively, before SCT to 63% predicted and 58% predicted, respectively, over an 18-month period after SCT (Figure 1 ). Lung function score (LFS) was 7 (moderate); National Institutes of Health (NIH) global cGVHD severity score, severe; NIH symptom-based lung score, 1; and NIH pulmonary function test (PFT)-based lung score, 2. 8, 9 She was given inhaled steroids and bronchodilators, without any improvement. Examination of a lung biopsy specimen obtained by videoassisted thoracoscopic surgery revealed findings compatible with BO. Given the lack of other approved BO therapies, we administered imatinib at a dose of 100 mg per day after obtaining written informed consent. The patient's dyspnea gradually improved, and her FEV 1 and DLco after 6 months of imatinib therapy increased from 63% predicted and 49% predicted, respectively, before imatinib to 82% predicted and 71% predicted, respectively ( Figure 1 ). The LFS improved to 3, the NIH symptombased lung score to 1 and the PFT-based lung score to 1. The patient has been followed for 1 year and has not developed any adverse effects associated with imatinib. Case 2 was a 31-year-old man who presented with progressive dyspnea on exertion. One year previously, he had undergone allo-SCT for CML. Four months after allo-SCT, he developed cGVHD involving his skin, liver and intestine; all lesions improved in response to corticosteroid and tacrolimus therapy. The patient developed exertional dyspnea 10 months after undergoing allo-SCT. His FEV 1 rapidly declined from 108% predicted before SCT to 50% predicted 1 year after the procedure, although his DLco did not change (97% predicted) (Figure 1) . LFS was 5 (mild); NIH global cGVHD severity score, severe; NIH symptom-based lung score, 1; and NIH PFT-based lung score, 2.
8,9 Examination of a lung biopsy specimen obtained by video-assisted thoracoscopic surgery revealed findings compatible with BO. The patient was also found to have increased copy numbers of M-BCR/ABL mRNA in a peripheral blood specimen, and he was diagnosed with molecular relapse of CML. Imatinib at 400 mg per day was started. After 7 months of therapy, M-BCR/ABL mRNA copies were undetectable, and his dyspnea gradually improved. His LFS, NIH symptom-based lung score and PFT-based lung score were unchanged after 6 months of imatinib treatment. Four years later, he started treatment using inhaled steroids and bronchodilators. Five years later, imatinib was changed to dasatinib because of generalized edema, and 3 years after that, dasatinib was changed to nilotinib because of pleural effusion. After 1 year of nilotinib, the patient developed an arrhythmia, and his treatment was changed to lowdose imatinib. The rate of decline of the patient's FEV 1 slowed over a 10-year period after the onset of BO and initiation of imatinib therapy, and the patient's dyspnea did not progress. The corticosteroid dose was tapered from 75 to 8 mg per day over 10 years to a final dose reduction of 89% (Figure 1) .
Representative pathological findings of a lung specimen (case 2) are shown in Figure 2 . Immunostaining revealed increased PDGFR-α expression in the peribronchial fibroproliferative lesions, and PDGFR-β expression in the peribronchial vascular smooth muscle cells (Figures 2b and c) . Kit expression was seen in some mast cells (Figure 2d) . No c-Abl expression was observed (data not shown).
We described two patients who developed BO following allo-SCT and who received TKIs for worsening BO in one case, and because of concurrent relapse of CML in the other case. The dyspnea of case 1 improved, with stabilization of her FEV 1 after she started treatment with a TKI. Case 2 achieved slowing in the decline and ultimate stabilization of his FEV 1 , and long-term survival during treatment with various TKIs. In addition, we found expression of PDGFR in the fibroproliferative peribronchial lesions typical of BO and in the vascular smooth muscle cells of the lung biopsy specimen before imatinib treatment.
A few clinical studies have assessed the efficacy of imatinib treatment for refractory cGVHD of the lung. Oliveri et al. 6 reported improved lung function in 7 of 10 patients (70%) with mild pulmonary cGVHD who received imatinib, and no response in a patient with moderately impaired lung function (LFS, 6). Stadler et al. 10 reported limited efficacy in patients (22%) with moderate-to-severe pulmonary cGVHD. However, our first patient (case 1), who had moderate cGVHD, obtained symptomatic and physiological improvement after she started taking imatinib, which suggests that imatinib might be effective for advanced cases of cGVHD. Furthermore, the previous studies determined response rates at 3 and 6 months after initiation of imatinib treatment. 6, 7 Our second patient (case 2) has achieved long-time survival with ultimate stabilization of FEV 1 , even though he did not appear to show improvement 6 months after initiation of imatinib. To the best of our knowledge, there have not been any published cases of cGVHD where the patient received continuous TKI therapy over a 10-year period and achieved long-term survival. Although 1-4 months of imatinib treatment for patients with moderate-to-severe pulmonary cGVHD has shown limited efficacy, 10 the response rate was improved when imatinib treatment was planned for at least 6 months, 7 suggesting that a longer duration of therapy may be more effective. In the absence of toxicity or intolerance, prolonged imatinib treatment may be beneficial for the treatment of BO.
Currently, lung transplantation is the only treatment option for patients with BO. However, lung transplantation has a number of problems, including shortage of donors, graft dysfunction and the morbidity associated with long-term immunosuppression. Ironically, BO is a serious cause of chronic lung allograft rejection. Imatinib can be given to BO patients who are waiting for lung transplantation or may even delay transplantation.
In conclusion, we described two patients with BO who were successfully treated with TKIs. Imatinib may be effective for patients with moderate and, possibly, severe pulmonary cGVHD, by contributing to the stabilization of FEV 1 , thereby achieving long-term survival, regardless of efficacy over the short term. Prospective clinical trials to assess the usefulness of TKIs for the treatment of BO are warranted.
